Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabumetone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabumetone SCHEMBL29373228 | 1.00 | CYP1A2 (1.00) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL29570823 | 1.00 | CYP1A2 (1.00) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL3853067 | 1.00 | CYP1A2 (1.00) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL28775077 | 0.98 | CYP1A2 (0.97) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL104942 | 0.98 | CYP1A2 (0.97) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL23064140 | 0.97 | CYP1A2 (0.94) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL7554060 | 0.95 | CYP1A2 (0.91) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL3362072 | 0.93 | RAB9A (0.86) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| Nabumetone SCHEMBL2325715 | 0.91 | CYP1A2 (0.83) | CYP1A2KDM4ELMNAMAPTNPC1 | |
| SCHEMBL17288829 | 0.90 | CYP1A2 (0.82) | CYP1A2KDM4ELMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 58523 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| US-4420639-A | Aromatic compounds | BEECHAM GROUP LIMITED (GB) | 1983-12-13 | — | — | US | claimed |
| EP-0043136-B1 | CUTTING DISK PROVIDED WITH PIGMENTS | HELIOTRONIC Forschungs- und Entwicklungsgesellschaft für Solarzellen-Grundstoffe mbH (DE) | 1983-11-30 | — | — | EP | claimed |
| EP-0003643-B1 | PROCESS FOR THE PREPARATION OF 4-(6-METHOXY-2-NAPHTHYL)-BUTAN-2-ONE; 4-(6-METHOXY-2-NAPHTHYL)-4-HYDROXYBUT-3-EN-2-ONE AND A PROCESS FOR ITS PREPARATION | BEECHAM GROUP PLC (GB) | 1982-09-29 | — | — | EP | claimed |
| US-4341239-A | Combination check-overpressure relief valve | VERNAY LABORATORIES, INC. (US) | 1982-07-27 | — | — | US | claimed |
| US-4312359-A | Noninvasive blood pressure measuring system | LIFE CARE SYSTEMS, INC. (US) | 1982-01-26 | — | — | US | claimed |
| US-4222725-A | Electro-hydraulic ram control apparatus | SOLID CONTROLS, INC. (US) | 1980-09-16 | — | — | US | claimed |
| US-4221741-A | Preparation of 4(6'-methoxy-2'-naphthyl)butan-2-one | BEECHAM GROUP LIMITED (GB) | 1980-09-09 | — | — | US | claimed |
| EP-0003643-A1 | Process for the preparation of 4-(6-methoxy-2-naphthyl)-butan-2-one; 4-(6-methoxy-2-naphthyl)-4-hydroxybut-3-en-2-one and a process for its preparation | BEECHAM GROUP PLC (GB) | 1979-08-22 | — | — | EP | claimed |
| US-4075840-A | Brake and steering system | CLARK EQUIPMENT COMPANY (US) | 1978-02-28 | — | — | US | claimed |
| US-4027482-A | Variable ratio hydraulic master-cylinder | ABRED ESTABLISHMENT (IT) | 1977-06-07 | — | — | US | claimed |